Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
ROCKVILLE, Md., May 02, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 13743533. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
